Envista Holdings Corp

NYSE:NVST

Medical - Equipment & Services

Healthcare
$23.75 +3.06%

+$0.76 today

Market cap
$3.81B
Beta
0.89
P/E (TTM)
62.0
EPS (TTM)
$0.41
52W Low $18.32High $30.42

Volume 1.92M

Average 2.94M

NVST Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Envista Holdings CorpNYSE: NVST

Net Margin · Q3 FY2026 · quarter ended Oct 2026

Net margin widens to 73.5%

Net margin was 73.5% in Q3 FY2026, up 78.0 pp from a year earlier. On a trailing-twelve-month basis it was 22.0%, up 21.4 pp year over year. Over 3 fiscal years it narrowed by 7.7 pp.

Context

  • Net margin widened in 1 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 11 analysts of 9.2% for the fiscal year ending Dec 2026, up from 1.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterOct 2026
73.5%+66.2 pp QoQ
Last fiscal yearDec 2025
1.7%+46.3 pp YoY
LTMOct 2026
22.0%+21.4 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+78.0 pp+4.4 pp-73.6 pp
1 year+46.3 pp+7.5 pp-38.8 pp
3 years-7.7 pp+7.7 pp+15.4 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
1.7%
Year-over-year change
+46.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How NVST compares with its peers on the latest reported figures

  • NVST's LTM Oct 2026 net margin of 22.0% is the highest of the 9 companies compared; the peer median is -6.4%.
  • Its year-over-year change of +21.4 pp is the 2nd highest of 9, against a peer median of +2.5 pp.
  • Over three fiscal years its change of -7.7 pp compares with a peer median of +5.6 pp.
NVST Competitors Peer median
Net Margin for NVST and competitors
Company Period LTM level YoY 3-year change
NVSTEnvista Holdings CorpLTM Oct 202622.0% +21.4 pp-7.7 pp
CONConcentra Group Holdings Parent, Inc.LTM Sep 20269.3% +1.9 pp-2.0 pp
ICUIICU Medical, Inc.LTM Jun 20261.4% +3.0 pp+3.3 pp
PRVAPrivia Health Group, Inc.LTM Jun 20261.2% +0.4 pp+1.7 pp
ALHCAlignment Healthcare, Inc.LTM Mar 20260.5% +3.5 pp+10.4 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-13.2% -22.9 pp-14.5 pp
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026-17.1% +7.4 pp+8.0 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-91.0% +2.0 pp+109.3 pp
GRALGRAIL, Inc.LTM Jun 2026-236.9% +92.9 pp+9441.9 pp
APGEApogee Therapeutics, Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
Peer median (excluding NVST) -6.4%+2.5 pp+5.6 pp

Competitors are the stored peer set for NVST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.51B2.57B2.57B2.51B2.72B
Cost of Revenue1.05B1.08B1.12B1.12B1.22B
Gross Profit1.46B1.49B1.45B1.39B1.5B
Gross Margin58.3%57.9%56.5%55.4%55.0%
Research & Development100.5M100.1M93.8M99.1M114M
Selling, General & Admin989.5M1.03B1.03B1.14B1.16B
Operating Expenses1.16B1.17B1.42B2.43B1.27B
Depreciation & Amortization151.9M162.1M162.6M123.1M116M
EBITDA524.3M522M490M279.5M329.8M
EBITDA Margin20.9%20.3%19.1%11.1%12.1%
Operating Income306.2M319.2M31.5M(1.04B)225.7M
Operating Margin12.2%12.4%1.2%-41.4%8.3%
Interest Income00000
Interest Expense54.1M38.4M63.4M46.4M36.6M
Other Income / Expenses(51.7M)(35.3M)(86.4M)(46.5M)(48.5M)
Income Before Tax254.5M283.9M(54.9M)(1.08B)177.2M
Pre-Tax Margin10.1%11.1%-2.1%-43.2%6.5%
Income Tax Expense(9M)45.9M45.3M33.9M130.2M
Net Income340.5M243.1M(100.2M)(1.12B)47M
Net Margin13.6%9.5%-3.9%-44.6%1.7%
EPS (Basic)1.631.46(0.60)(6.50)0.28
EPS (Diluted)1.481.34(0.60)(6.50)0.28
Weighted Avg Shares161.2M162.9M166.9M172.2M168M
Weighted Avg Shares (Diluted)177.6M177.6M166.9M172.2M169.2M

Envista Holdings Corp

NYSE:NVST

Intrinsic Alpha fair value

Locked

Current Price

$23.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.